Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China Shows More Of An Open Door To Overseas Medtech Industry

Executive Summary

China's influence on global medtech regulation and the country's continuing emergence on the world stage will be felt increasingly in the coming years. But while China may be less inclined to exclude big medtech multinationals, it feels no compulsion to harmonize totally with the US and/or EU systems.

You may also be interested in...

APACMed 2020: Dynamic China Market Will Heed COVID-19 Lessons For System Improvement In '21

To the watching world, China dealt quickly and firmly with COVID-19. Seen from within, the health care system is still adapting to the pandemic, but the government is taking the longer view.

US Trade Rep Details Seven Ways China Unfairly Competes With US Device Manufacturers

US and foreign device manufacturers are being systematically discriminated against in their attempts to sell their medtech products in China, and in working with Chinese regulatory authorities to build successful and beneficial partnerships with China device-makers, says a new report from the US Trade Representative’s office.

Industry Responds To Vietnam's Draft Decree 36, And Justifies 2020 Deadline Extension

Medtech companies' chance to comment on the final draft of amendments to Vietnam's medical device regulations closed in mid-June. The Vietnam Ministry of Health released a translation of the draft to allow multinational companies and other foreign stakeholders full access to the ongoing debate on extending the deadline to the end of 2019, as proposed by industry in the latest exchanges.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts